1	Title: Long-term Mortality Among Hospitalized Adults with Sepsis in Uganda: a Prospective
2	Cohort Study
3	
4	Authors: Paul W. Blair, MD* ^{1,2} ; Stephen Okello, MD ³ ; Abdullah Wailagala, MD ⁴ ; Rodgers R. Ayebare,
5	MD ⁴ ; David F. Olebo, BS ³ ; Mubaraka Kayiira, MD ⁴ ; Stacy M. Kemigisha MD ⁴ , Willy Kayondo, BS ³ ;
6	Melissa Gregory, MS ¹ ; Jeff W. Koehler, PhD ⁵ ; Randal J. Schoepp, PhD ⁵ ; Helen Badu, MBA ¹ ; CDR
7	Nehkonti Adams, MD, MS ⁶ ; Prossy Naluyima PhD ³ ; Charmagne Beckett, MD ⁶ ; Peter Waitt, MBChB ⁴ ;
8	Mohammed Lamorde, FRCP, PhD ⁴ ; Hannah Kibuuka, MD ³ ; Danielle V. Clark, PhD ¹
9	
10	
11	Affiliations:
12	¹ The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD,
13	USA;
14	² Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD,
15	USA;
16	³ Makerere University Walter Reed Project, Kampala, Uganda;
17	⁴ Infectious Diseases Institute, Makerere University, Kampala, Uganda;
18	⁵ U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick,
19	Frederick, Maryland, USA;
20	⁶ Naval Medical Research Center Infectious Diseases Directorate, Bethesda, MD, USA.
21	
22	*Corresponding author
23	
24	
25	

2	6
_	-

27 Abstract–198 words

- 28 Background: Twelve-month mortality in sepsis survivors has not been previously characterized in sub-
- 29 Saharan Africa.
- **30** Methods: Hospitalized adults with ≥ 2 modified systemic inflammatory response syndrome (SIRS)
- 31 criteria (temperature $< 36^{\circ}$ C or $> 38^{\circ}$ C, heart rate ≥ 90 beats per minute, or respiratory rate ≥ 20 breaths
- 32 per minute) were enrolled at a tertiary care centre from October 2017 to August 2022. Multiple clinical
- 33 blood and respiratory molecular and antigen assays were used to identify infectious etiologies. Baseline
- 34 demographics were evaluated for risk of death by 1 month and 12 months using Cox proportional hazards
- 35 regression.
- **Results:** Among 435 participants, the median age was 45.0 years (interquartile range [IQR]: 28.0, 60.0)
- 37 years, 57.6% were female, and 31.7% were living with HIV. Malaria (17.7%) followed by tuberculosis
- 38 (4.7%), and bacteremia (4.6%) were the most common detected causes of illness. Overall, 49 (11.3%)
- 39 participants died, and 24 participants died between one month and one year (49.0% of deaths and 5.5% of
- 40 the cohort). Female participants had a decreased risk of death by 12-months (unadjusted hazard ratio
- 41 [HR]: 0.37; 95% confidence interval [CI]: 0.21 to 0.66).
- 42 Conclusions: The burden of sepsis may be underestimated in sub-Saharan Africa due to limited long-43 term follow-up.
- 44 Keywords: Sepsis, Bloodstream infection, HIV, Sepsis/epidemiology, Africa South of the Sahara
- 45
- 46
- 47
- 48
- 49
- -
- 50
- 51

52 Text – 3,097 words

53 Introduction

54 In 2017, 11 million deaths occurred due to sepsis¹. The burden of sepsis is highest in low- and middle-

- 55 income countries (LMIC), settings where treatment resources are lowest ¹. Long-term mortality after
- sepsis is high, ranging from 28 to 66% over 12 months ². However, long-term outcomes after sepsis in
- 57 LMICs are largely unknown with only one, to our knowledge, prospective study past 28-days ³ and the
- 58 overwhelming majority of studies coming from North American and Europe. There have been no
- 59 published studies from sub-Saharan Africa (SSA) describing post-sepsis mortality at 12-months ²⁻⁵.
- 60

61 We conducted a prospective observational study to characterize severe infectious disease pathogens,

62 clinical manifestations, and host response among patients presenting for care at Fort Port Regional

63 Referral Hospital in Fort Portal, Uganda⁶. One purpose of the study has been to build a continuous base of

64 severe infectious disease clinical research operations and training in preparation for more complex

65 protocols, including interventional clinical trials⁶. We describe long-term (12-month) outcomes after five

66 years of enrollment, causes of sepsis, and the mortality risk associated with baseline clinical

67 characteristics.

68

69 Materials and Methods

70 Persons 18 years of age and older presenting with suspected infection and ≥ 2 modified systemic 71 inflammatory response syndrome (SIRS) criteria (temperature $< 36^{\circ}$ C or $> 38^{\circ}$ C, heart rate ≥ 90 beats per 72 minute, or respiratory rate > 20 breaths per minute) were enrolled at Fort Portal Regional Referral 73 Hospital (FPRRH) in Fort Portal, Uganda. SIRS was incorporated in sepsis cohorts⁷ prior to Sepsis 3 74 criteria⁸ and maintained for consistency. Adult patients 18 years of age and older presenting at the 75 outpatient department, emergency department, or medical wards were evaluated for enrollment from 76 October 2017 to August 2022. Patients were not eligible if they were deemed too ill to participate with an 77 imminently terminal comorbidity or if they presented with severe anaemia (hemoglobin<7 g/dL) due to

78 phlebotomy requirements. Due to initial inflammation biomarker objectives⁹, participants were excluded 79 with known immunocompromising conditions including drug induced immunosuppression, anatomic or 80 functional asplenia, recent chemotherapy, pregnancy and <6 weeks post partum females, but participants 81 with HIV were eligible. FPRRH serves as a health facility to eight districts in western Uganda 82 (Supplementary Figure S1) and includes an isolation unit for referral of patients with high consequence 83 pathogens including during the 2022 Sudan virus disease outbreak ^{6,10,11}. After screening potential 84 participants, 435 participants enrolled from October 2017 to August 2022. The study team collected 85 demographic, clinical, and laboratory data at 0, 6, and 24 hour time points after enrollment and at 72 86 hours starting after the first 260 enrollments. Study participants were followed until discharge and at 1 month when a physical exam, history, and labs were also done. Telephone follow-ups were done at 6-87 88 months and 12-months. All clinical and laboratory data were recorded daily by designated study staff on 89 the case report forms. Survival was determined during in-person visits or telephone calls when 90 participants could not attend in-person visits. There were 398 participants at 28-days follow-up, 383 91 participants at 6-month follow-up, and 338 participants at 12-month follow-up (Figure 1). 92

93 Physiologic parameters (heart rate, blood pressure, oxygen saturation, and temperature) were 94 prospectively collected at study visits at enrollment, 6 hours, and 24 hours while hospitalized and at in-95 person follow-up visits. After enrollment, an i-STAT analysis (Abbott, Chicago, IL) for lactate and blood 96 gases was performed on blood collected at scheduled at 0, 6, and 24 hour study visits. Clinical tests were 97 routinely performed including complete blood counts, coagulation analyses, and chemistries. Diagnostic 98 testing included blood culture with antimicrobial sensitivity testing, urinalysis, HIV testing with consent, 99 malaria smears and malaria rapid diagnostic tests were routinely performed. If there was blood culture 100 growth, the BCID FilmArray (Biofire, Salt Lake City, Utah, USA) assay was run for bacterial species 101 confirmation. If there was clinical suspicion based on respiratory symptoms, testing for tuberculosis was 102 performed using PCR sputum testing (Xpert MTB/RIF Ultra, Cepheid, California, USA). Patients with

103 known COVID-19 were not enrolled until June 2021. Hospital-based COVID-19 testing (rapid diagnostic tests or PCR) was recorded until replaced by multiplex PCR sputum testing (Xpert® Xpress SARS-CoV-104 105 2/Flu/RSV, Cepheid, California, USA) in July 2022 for those with respiratory symptoms. If HIV testing 106 was positive, urine lipoarabinomannan (Abbott TB LAM Ag, Illinois, United States) testing was 107 performed. The Biofire FilmArray Global Fever polymerase chain reaction (PCR) panel (Biofire, Utah, 108 USA) was run on whole blood samples to identify 19 bacterial, viral, or protozoal targets or plasma if 109 whole blood was unavailable (first 36 participants)¹². Plasma samples were run in duplicate with a 110 Crimean-Congo hemorrhagic fever virus real-time RT-PCR assay targeting the NP gene using previously 111 described methods ¹³⁻¹⁵ but replaced after transition of the Global Fever panel from off-site to on-site use 112 after the first 237 participants. Extracted nucleic acid (5 µl) from plasma samples from the first 237 113 participants were run with a Crimean-Congo hemorrhagic fever virus real-time RT-PCR assay targeting 114 the NP gene in duplicate using the using SuperScript One-Step RT-PCR Kit (ThermoFisher Scientific) 115 using previously described methods ¹³⁻¹⁵. Primers (CCHFV-S-F649 5'GGAVTGGTGVAGGGARTTTG 116 and CCHFV-S-R705 5'-CADGGTGGRTTGAARGC) were at 5 µM concentrations, and the probe 117 (CCHFV-S-p670 FAM-CAARGGCAARTACATMAT-MGBNFQ) was at 0.1 µM M. Cycling conditions 118 were 50°C for 15 min; 95°C for 5 min; and 45 cycles at 94 °C for 1 s, 55 °C for 20 s, and 68 °C for 5 s. 119 Fluorescence was measured after each extension step, and a sample was considered negative if the 120 quantification cycle (Cq) was greater than 40 cycles.

121

122 Analysis

Summary statistics were performed for baseline characteristics and microbiology results. Baseline
demographics were compared between those that completed followed to those that did not (were
withdrawn or lost-to-follow-up, 6.4%) using the Kruskal-Wallis test. Person-time was administratively
censored at the known last visit among those who were lost-to-follow-up or withdrawn. After checking
the proportional hazards assumption using Schoenfeld residuals and log-log plots (resulting in exclusion)

128	of platelet count and dichotomizing respiratory rate), baseline characteristics of age, sex, HIV status,
129	clinical laboratory results, qSOFA score were evaluated for their association with 28-days and 12-month
130	survival with Cox regression models. The logrank test was performed to evaluate for a difference in
131	survival based on HIV status or sex. Sepsis severity clinical decision tools were dichotomized for
132	bivariate models according to current usage, including qSOFA score ≥ 2 (range, 0 [best] to 3 [worst]
133	points)cand UVA score ≥ 2 (range, 0 [best] to 13 [worst]) ¹⁶ . Bivariate analyses were exploratory;
134	therefore, a p-value correction was not performed.
135	
136	Enrollment in the Fort Portal sepsis cohort to a sample size up to 1,075 participants is planned to estimate
137	the risk of emerging pathogens with a precision of 3%. We herein present results from the first 435
138	participants to disseminate clinical epidemiologic information, inform clinicians about the differential
139	diagnosis of severe infection in Uganda, and describe long-term outcomes after the first five years of
140	enrollment. A map of Uganda was created using ArcGIS ArcGIS Online (Redlands, CA) ¹⁷ . Analyses were
141	performed using Stata, version 16.0 (StataCorp LLC, College Station, TX, USA), and figures were
142	created using Stata or R, version 4.0.1 (R Foundation).
143	
144	Results
145	Participants were a median (IQR) of 42.0 (28.0 to 57.0) years of age at enrollment and 59.1% were female
146	(n=257) (Table 1). A diagnosis of human immunodeficiency virus (HIV) was common (31.7%; n=138)
147	of which 17.4% (n=24) were new diagnoses. Otherwise, known comorbid illness was uncommon (Table
148	1). At enrollment, there were 21.2% (n=91) with a qSOFA score of \geq 2. Tachypnea and tachycardia was
149	common but most participants were normotensive and afebrile (Table 1). The median duration of
150	hospitalization was 3.0 days (IQR: 2.0 to 5.0 days).
151	
150	Diagnoses alivial migrophiclogy and antibiotics

152 *Diagnoses, clinical microbiology, and antibiotics*

153 Among the 32.4% (141 of 435 participants) with a positive microbiologic result, malaria was the most 154 common cause of illness. There were 6.3% (27 of 424) with positive malaria smears and 17.7% (75 of 155 425) with positive malaria rapid diagnostic tests (Table 3). Among 43 RDT positive samples with smear 156 quantification results, the median parasitemia was 10,240 (IQR: 1,680, 60,000) parasites/µL of blood. The 157 Global Fever PCR panel was most frequently positive from *Plasmodium spp.* (25.4%; 102 of 401) or 158 specifically P.falciparum (19.5%, 78 of 401). 159 Non-malarial positive Global Fever panel PCR results were uncommon but included two cases of 160 Leptospira *spp.*, and one case of *Salmonella enterica* serovar *Typhi*. A single positive CCHF virus result 161 was obtained with single-plex RT-PCR and confirmed with national referral laboratory testing at the 162 Uganda Viral Research Institute. Intrerestingly, this CCHF case was a 25-year-old woman with one week 163 of fevers and chills with no hemorrhagic symptoms, a normal complete blood count, and only a borderline 164 elevated AST (30 U/L) on the complete metabolic panel. Hospital-based COVID-19 testing was positive 165 in 32.7% (35 of 107 participants). Results including a Delta variant surge¹⁸ from June 2021 to December 166 2021 were positive in 58.3% (28 of 48 participants tested) but positivity decreased to 11.9% (7 of 59 167 participants tested) from January 2022 to August 2022. 168 The most frequent confirmed non-malarial causes of sepsis were tuberculosis and bacteremia. Of 160 169 participants able to produce sputum samples, 10.6% (17 of 146 with sputum) were positive for M. 170 tuberculosis by Cepheid GeneXpert. Among those with HIV and urine samples, 5.0% (5/121) had 171 positive LAM results including 3 without sputum Cepheid GeneXpert testing resulting in 20 total 172 tuberculosis cases (4.6% of the cohort). Out of 414 participants with blood cultures, there was growth 173 among 4.6% (N=19) of participants and Streptococcus pneumoniae (N=7; 1.7%) was the most common 174 isolate (Table 2). One out of 1 cerebrospinal fluid cultures grew Cryptococcus neoformans. The most 175 common antimicrobials received among participants included ceftriaxone (85%), metronidazole (34.7%), 176 azithromycin (27.8%), artesunate (17.5%), and ciprofloxacin (17.2%). Notably, 7.8% received anti-

tuberculosis treatment and 6.4% received doxycycline or tetracycline. Among those with microbiologic

testing, 32.9% (141 of 428 participants) had a positive result. Majority (36 of 49, 73.5%) of deaths did not

have a microbiologic diagnosis. Among those with positive results, testing indicated tuberculosis (n=3),
malaria (n=3), bacteremia (n=4) and COVID-19 (n=4).

181

182 *Risk of death at 28-days and 12-months*

183 Overall, 49 (11.3%) participants died. By 28-days, 25 (5.7%) participants died, and 24 deaths occurred

between 28-days and 12-months (49.0% of deaths and 5.5% of the cohort). Among those with a qSOFA

 ≥ 2 at enrollment, 18.8% (17 of 91 participants) died by 12-months. Compared to the rest of the cohort,

those lost-to-follow-up had a similar age (median 44, IQR: 33.5 to 59.0 years; p=0.29), female sex

187 (50.0%; p=0.31), prevalence of HIV (25.0%, p=0.43) and baseline qSOFA score (median 1, IQR: 1 to 1;

188 p=0.90). Death occurred a median of 46.0 (IQR: 7.0 to 178.0) days from enrollment and 38.8% of those

that died had HIV. In bivariate analyses, while age was not associated with increased risk of death, female

190 participants had a lower risk of death over 28-days (HR: 0.44;95% CI: 0.21 to 0.75; Supplementary

191 Figure S2A) and 12-months (HR: 0.37; 95% CI: 0.21 to 0.66, logrank test p<0.001, Figure 2A and Figure

192 3A) than male participants. People with HIV were not observed to have an increased risk of death over

193 28-days (HR: 1.02; 95% CI: 0.44 to 2.36) or 12-months (HR: 1.38; 95% CI: 0.77 to 2.44; logrank test

194 p=0.19). Baseline physiologic metrics were associated with an increased risk of death over both 28-days

and 12-months including an increased heart rate, decreased oxygen saturation, decreased mental status,

196 qSOFA score \geq 2, and UVA score \geq 2 (Figure 2C-D, Figure 3A). Clinical laboratory parameters associated

197 with increased risk of death over 28-days and 12-months included decreased serum sodium, increased

198 neutrophil/lymphocyte ratio, increased AST, increased creatinine, and increased lactate (Supplementary

199 Figure S2B and Figure 3B). A positive malaria RDT was not associated with a difference in risk of death

200 over 28-days (HR: 0.40; 95% CI: 0.09 to 1.70) but was associated with a decreased risk of 12-month

201 mortality (HR: 0.30; 95% CI: 0.09 to 0.96)(Figure 3C). Any microbiologic diagnosis was not associated

202 with a difference in risk of death over 28-days (HR: 0.96, 95% CI: 0.41 to 2.23) or 12-months (HR: 0.73,

203 95% CI: 0.39 to 1.37).

204

205 Discussion

Our study is the first to describe mortality at one year after generalized sepsis in a well-characterized large prospective cohort in sub-Saharan Africa (SSA) ^{3,5}. We identified that almost half of deaths among adults that presented with suspected sepsis occurred after 28-days. The most common causes of illness were malaria, tuberculosis, and bacteremia, and an unsuspected case of CCHF was identified. COVID-19 was the most common cause of illness during a 2021 surge. The majority of causes of illness were unknown despite multiple clinical microbiologic assays.

212

213 There is a paucity of long-term outcome data in SSA. In a meta-analysis of 15 studies of sepsis in SSA 214 performed in 2019, none had results of mortality after 30 days ⁵. Compared to the 11.3% 12-month 215 mortality we observed, the pooled in-hospital sepsis mortality among those meeting SIRS score of ≥ 2 216 from 7 cohort studies with enollment years ranging from 2008 to 2013 was 19% (95% CI, 12 to 29%, 217 n=1159)⁵. HIV status was not associated with a difference in risk of mortality, consistent with a recent 218 small acute febrile illness cohort in Uganda with a similar baseline prevalence of an elevated qSOFA 219 score ¹⁹. The similar risk of death observed among those with HIV is potentially a testament to outcome 220 improvements from increased access to outpatient antiretroviral treatment ^{19,20}. However, this may not be 221 generalizable to other countries in SSA. Patients with HIV had a higher risk of death in a recent sepsis 222 cohort in Malawi³. In that study, death was observed in 18% at 28-days and in 31% at 180 days. Overall 223 lower death rates in our cohort may have been due to baseline patient population differences, including 224 nonspecificity of SIRS criteria for sepsis eligibility⁷, or advancements in clinical care at the Fort Portal 225 site ⁶. Long-term mortality may be higher in more severely ill individuals or in other settings with less 226 resources for sepsis management. Standardized multi-site cohorts and surveillance studies are needed for 227 definitive conclusions.

228

Although sepsis syndrome is likely a final common pathway for many of these infectious diseases-related
deaths, few studies from SSA have provided insight into the microbiologic diagnoses of these patients. A

231 meta-analysis of African bacteremia studies reported a 10% prevalence of bloodstream infections ²¹. A more recent 2019 meta-analysis demonstrated that tuberculosis dominates as a cause of sepsis in SSA ⁵. 232 233 Similar to our findings, standard clinical microbiological laboratory analysis for bacterial, mycobacterial, 234 and malarial pathogens were detected a cause in only $\sim 30\%$ of cases, most commonly *Mycobacterium* 235 tuberculosis, non-typhoidal Salmonella, Staphylococcus aureus, and Streptococcus pneumoniae. A recent 236 study of adult and paediatric patients hospitalized with acute febrile illness in Tanzania were discovered 237 to have acute bacterial zoonoses as the most common group of aetiologies (26.2%) including 238 leptospirosis, Q fever, and spotted fever group rickettsioses, none of which are identified by standard 239 culture methods ²². 240 241 Our findings highlighted the public health utility of ongoing infectious illness cohorts. Our study

242 identified a case of CCHF that otherwise would not have been detected. Similarly, CCHF was previously 243 identified at the Global Fever panel febrile illness study site in Mubende, Uganda ^{12,23}. During the 2022 244 Sudan virus disease outbreak. multiple suspect Ebola cases have been identified as CCHF. Detection of 245 these cases suggests that CCHFV is an uncommon but persistent cause of suspected sepsis or febrile 246 illness in Uganda and that cases without fulminant hemorrhagic symptoms likely occur undetected 247 outside of outbreaks. Additionally, we identified COVID-19 as the most common causes of suspected 248 sepsis in this remote referral hospital during a local surge¹⁸. Our finding emphasize the unaccounted 249 burden of admissions during outbreaks and subsequent deaths due to outbreaks and emerging infectious 250 diseases in low-resource and remote settings. As emerging infectious disease threats become more 251 commonplace and with challenges from known endemic threats, highlighted by the 2022 Sudan virus 252 outbreak in Uganda ¹¹, our need to rapidly recognize and effectively manage these causes of severe 253 infection grows more urgent. In recent years, several public health emergencies of international concern 254 were first detected in critically ill patients, patients meeting the diagnostic criteria for sepsis. Scaling and 255 developing point-of-care diagnostics would help facilitate early recognition of emerging causes of sepsis 256 to initiate infection control, supportive treatment, and reporting of emerging infectious diseases.

257

258	We identified several clinical parameters associated with death by 28-days and by 12-months. Consistent
259	with prior studies ^{3,19} , decreased oxygen saturation was found to be associated with an increased risk of
260	death. Patients with respiratory failure may be at particularly risk in hospitals without respiratory support
261	including high flow nasal cannula and mechanical ventilation or access to supplemental oxygen upon
262	discharge. Elevated UVA scores, qSOFA scores, and point-of-care lactate were each associated with an
263	increased risk of death consistent with prior studies in LMICs 7,16,24. Prior research that demonstrated the
264	additive prognostic value of serum lactate in Uganda, Malawi, and Southeast Asia 3,25,26. A positive
265	malaria result was associated with a decreased risk of death at 12-months. While this finding is tempered
266	by multiple comparisons, a protective association was observed in the Malawi cohort ³ . Malaria in adults
267	with suspected sepsis may be less fatal due to longstanding immunity, access to diagnostics, and
268	commonly employed empiric anti-malarial treatment regimens. Detection of any pathogen was not
269	associated with risk of death but inference is complicated by intrinsic pathogen differences, effects on
270	treatment decisions, and increased assay sensitivity with higher inoculum infections. Future research
271	should be performed to evaluate the effect of point-of-care diagnostics for decreasing time to accurate
272	treatments.

273

274 Our study has several limitations. First, while laboratory testing in this cohort was robust and included a 275 broad molecular panel, blood cultures, and rapid diagnostic tests, tuberculosis and rickettsial infections 276 were likely missed but current point-of-care diagnostics are limited for these pathogens. CD4 or HIV viral 277 load results were not routinely available, preventing inference about level of HIV control. Second, the 278 effect of sepsis on quality of life at one month was not ascertained at follow-up visits. Future research 279 plans to include surveys to determine the long-term burden of sepsis on quality of life. Third, despite 280 similar baseline characteristics, those lost to follow-up may have been more at risk for death; our estimate 281 of long-term mortality may be underestimated. Despite limitations, to our knowledge this is the first 282 cohort study in SSA to describe long-term mortality to 12-months after suspected sepsis.

283

284 Conclusions

Almost half of the deaths observed overall occurred during the observation period from one month to one
year. The burden of sepsis in SSA is likely underestimated. Patients discharged after admission for sepsis

287 likely represent a vulnerable population that should have a longitudinal follow-up for medical care.

288

289 Declarations

290 This protocol and informed consent were approved by the U.S. Army Medical Research and Development

291 Command Institutional Review (# M-10573) and Makerere University School of Public Health IRB#

490). All participants provided written consent that was provided in either English or their local language.

All procedures were in accordance with the ethical standards of the Helsinki Declaration of the World

294 Medical Association. The investigators have adhered to the policies for protection of human subjects as295 prescribed in 45 CFR 46.

296

297 The contents of this article are the sole responsibility of the authors and do not necessarily reflect the 298 views, assertions, opinions, or policies of the Henry M. Jackson Foundation for the Advancement of 299 Military Medicine, Inc., the U.S. Department of Defense, the U.S. government, or any other government 300 or agency. Mention of trade names, commercial products, or organizations does not imply endorsement 301 by the U.S. government. Some of the authors of this work are military service members or employees of 302 the U.S. government. This work was prepared as part of their official duties. Title 17 U.S.C. x105 303 provides that "Copyright protection under this title is not available for any work of the United States 304 government." Title 17 U.S.C. x101 defines a U.S. government work as a work prepared by a military 305 service member or employee of the U.S. government as part of that person's official duties.

306

307	Acknowledgments. We would like to thank all of the Fort Portal research nurses, laboratory technicicians,
308	and hygienists and the medical staff. We would also like to thank David Brett-Major, MD, James Lawler,
309	MD, Nahid Bhadelia, MD, and Karen Martins, PhD for their contributions to the Fort Portal research site.
310	
311	Author contributions. PWB conceived and designed the study, analyzed, and interpreted data, and wrote
312	the manuscript. DFO, AW, SO, and MK collected data. SO, MG, RJS, PW and HB contributed to project
313	execution. ML, CB, HK, and DVK oversaw project execution and contributed to obtaining resources. PN,
314	AW, DFO, HK, RJS, and PW contributed to interpretation of results. All authors reviewed and approved
315	this manuscript.
316	
317	Financial support. This project was supported by Joint Program Executive Office (JPEO-EB) W911QY-
318	20-9-0004 (2020 OTA). Pathogen testing supported by Naval Medical Logistics Command (NMLC)
319	cooperative agreement N626451920001.
320	
321	Conflicts of interests. The authors have no financial interests to declare.
322	
323	References
324	1. Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and
325	mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet (London, England) 2020;
326	395 (10219): 200-11.
327	2. Gritte RB, Souza-Siqueira T, Curi R, Machado MCC, Soriano FG. Why Septic Patients Remain
328	Sick After Hospital Discharge? Front Immunol 2020; 11: 605666.
329	3. Lewis JM, Mphasa M, Keyala L, et al. A longitudinal observational study of aetiology and long-
330	term outcomes of sepsis in Malawi revealing the key role of disseminated tuberculosis. Clinical infectious
331	diseases : an official publication of the Infectious Diseases Society of America 2021.

- 332 4. Winters BD, Eberlein M, Leung J, Needham DM, Pronovost PJ, Sevransky JE. Long-term
- mortality and quality of life in sepsis: a systematic review. *Critical care medicine* 2010; **38**(5): 1276-83.
- 5. Lewis JM, Feasey NA, Rylance J. Aetiology and outcomes of sepsis in adults in sub-Saharan
- Africa: a systematic review and meta-analysis. *Crit Care* 2019; **23**(1): 212.
- 336 6. Martins KA, Ayebare RR, Bhadelia N, et al. Pre-positioned Outbreak Research: The Joint
- 337 Medical Emerging Diseases Intervention Clinical Capability Experience in Uganda. *Health security* 2020;
- **18**(2): 114-24.
- 339 7. Blair PW, Mehta R, Oppong CK, et al. Screening tools for predicting mortality of adults with
- 340 suspected sepsis: an international sepsis cohort validation study. *BMJ Open* 2023; **13**(2): e067840.
- 341 8. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions
- 342 for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016; **315**(8): 801-10.
- 343 9. Krishnan S, Beckett C, Espinosa B, Clark DV. Austere environments Consortium for Enhanced
 344 Sepsis Outcomes (ACESO). *Shock (Augusta, Ga)* 2020; **53**(3): 377-8.
- 345 10. Naluyima P, Kayondo W, Ritchie C, et al. The joint mobile emerging disease clinical capability
- 346 (JMEDICC) laboratory approach: capabilities for high-consequence pathogen clinical research. PLoS
- 347 *neglected tropical diseases* 2019; **13**(12): e0007787.
- 348 11. Kiggundu T, Ario AR, Kadobera D, et al. Notes from the Field: Outbreak of Ebola Virus Disease
- 349 Caused by Sudan ebolavirus Uganda, August-October 2022. MMWR Morb Mortal Wkly Rep 2022;
- **350 71**(45): 1457-9.
- 351 12. Manabe YC, Betz J, Jackson O, et al. Clinical evaluation of the BioFire Global Fever Panel for
- the identification of malaria, leptospirosis, chikungunya, and dengue from whole blood: a prospective,
- 353 multicentre, cross-sectional diagnostic accuracy study. *Lancet Infect Dis* 2022.
- 13. Nimo-Paintsil SC, Mosore M, Addo SO, et al. Ticks and prevalence of tick-borne pathogens from
- domestic animals in Ghana. *Parasites & vectors* 2022; **15**(1): 86.

- 14. Koehler JW, Delp KL, Hall AT, et al. Sequence Optimized Real-Time Reverse Transcription
- 357 Polymerase Chain Reaction Assay for Detection of Crimean-Congo Hemorrhagic Fever Virus. Am J Trop

358 *Med Hyg* 2018; **98**(1): 211-5.

- 359 15. Voorhees MA, Padilla SL, Jamsransuren D, et al. Crimean-Congo Hemorrhagic Fever Virus,
- 360 Mongolia, 2013-2014. *Emerg Infect Dis* 2018; **24**(12): 2202-9.
- 361 16. Adegbite BR, Edoa JR, Ndzebe Ndoumba WF, et al. A comparison of different scores for
- 362 diagnosis and mortality prediction of adults with sepsis in Low-and-Middle-Income Countries: a
- 363 systematic review and meta-analysis. *EClinicalMedicine* 2021; **42**: 101184.
- 17. Environmental Systems Research Institute I. ArcGIS. Redlands, CA: ArcGIS Online; 2022.
- 365 18. Bakamutumaho B, Lutwama JJ, Owor N, et al. Epidemiology, Clinical Characteristics, and
- 366 Mortality of Hospitalized Patients with Severe COVID-19 in Uganda, 2020–2021. Annals of the
- 367 *American Thoracic Society* 2022; **19**(12): 2100-3.
- 368 19. Blair PW, Kobba K, Kakooza F, et al. Aetiology of hospitalized fever and risk of death at Arua
- and Mubende tertiary care hospitals in Uganda from August 2019 to August 2020. *BMC infectious*
- **370** *diseases* 2022; **22**(1): 869.
- Otieno G, Whiteside YO, Achia T, et al. Decreased HIV-associated mortality rates during scaleup of antiretroviral therapy, 2011-2016. *Aids* 2019; 33(15): 2423-30.
- 373 21. Reddy EA, Shaw AV, Crump JA. Community-acquired bloodstream infections in Africa: a
- 374 systematic review and meta-analysis. *Lancet Infect Dis* 2010; **10**(6): 417-32.
- Crump JA, Morrissey AB, Nicholson WL, et al. Etiology of severe non-malaria febrile illness in
 Northern Tanzania: a prospective cohort study. *PLoS Negl Trop Dis* 2013; 7(7): e2324.
- 377 23. Jones BW RD, Gurling MA, Veloz M, Jackson O, Burton M, Batty N, Belgique P, Andjelic CA,
- **378** & Phillips CA. Clinical Evaluation of the BioFire® FilmArray® Global Fever Panel. Poster C-1803.
- 379 American Society of Tropical Medicine & Hygiene (ASTMH) Annual Meeting; 2019 November 20 24,
- 380 2019; Washigton, DC; 2019.

381	24.	Moore CC, Jacob ST.	Pinkerton R.	, et al. Point-of-care l	lactate testing p	redicts mortality	of severe
				· · · · · · · · · · · · · · · · · · ·			

382 sepsis in a predominantly HIV type 1-infected patient population in Uganda. *Clinical infectious diseases* :

an official publication of the Infectious Diseases Society of America 2008; 46(2): 215-22.

- 384 25. Wright SW, Hantrakun V, Rudd KE, et al. Enhanced bedside mortality prediction combining
- 385 point-of-care lactate and the quick Sequential Organ Failure Assessment (qSOFA) score in patients
- hospitalised with suspected infection in southeast Asia: a cohort study. *Lancet Glob Health* 2022; **10**(9):
- **387** e1281-e8.
- 388 26. Moore CC, Jacob ST, Jacob ST, et al. Point-of-care lactate testing predicts mortality of severe
- 389 sepsis in a predominantly HIV type 1–infected patient population in Uganda. *Clinical Infectious Diseases*
- **390** 2008; **46**(2): 215-22.
- 391

392 Figure legends.

- 393 Figure 1. Cohort flow diagram.
- 394 Figure 2. Kaplan-Meier plots by sex (A), HIV status (B), qSOFA score (C), and UVA score (D).
- 395 Figure 3. Hazard ratio forest plot of 12-month mortality risk associated with baseline demographics and
- 396 vital signs (A), clinical laboratory results (B), and clinical microbiology results (C). Min.:Minute,
- 397 qSOFA: quick Sepsis Organ related Failure Assessment; Pos.: positive; UVA: Universal Vital
- 398 Assessment.
- 399







Figure 1. Cohort flow diagram.

Demographics and vital signs	n
Female sex	426
Glasgow Coma Score	
Oxygen saturation (%)	
Mean arterial pressure (mmHg)	
Age, yrs	
Heart rate (beats/min.)	
Respiratory rate >22 breaths/min.	
UVA score (per point)	423
qSOFA score (per point)	425

HR	CI	р
0.37	(0.210.66)	<0.001
0.47	(0.260.85)	0.013
0.89	(0.840.93)	<0.001
1.00	(0.981.02)	0.827
1.01	(1.001.03)	0.108
1.03	(1.011.04)	<0.001
1.25	(0.562.79)	0.582
1.43	(1.261.62)	<0.001
1.87	(1.153.03)	0.011

	for use under a CC0 license.	
inical laboratory results	n	

Clinical laboratory results	n	_				
Hemoglobin (g/dL)	398				•	
Sodium (mEq/L)	425				+	
Lymphocyte differential (%)	398				•	
Neutrophil differential (%)					•	
Eosinophil differential (%)	335				+	
ALT (per 100 U/L)	425				+	
White blood count (x 10 ³ /žL)	398				•	
Neutrophil/lymphocyte r atio					•	
AST (per 100 U/L)	424				_ ♦-	
Creatinine (mg/dL)	421				_ i ◆	
Lactate (mmol/L)	409				- ¦⊣	►
		0.10	0.25	0.50	1.00	2.00 3.00
Microbiology results	n	- 1			1	

423

HR	CI	р
0.88	(0.790.99)	0.028
0.95	(0.901.00)	0.065
0.99	(0.971.02)	0.462
1.01	(0.991.03)	0.363
1.01	(0.841.22)	0.909
1.04	(0.861.25)	0.708
1.05	(1.011.10)	0.016
1.06	(1.031.10)	<0.001
1.12	(1.001.26)	0.050
1.20	(1.111.31)	<0.001
1.40	(1.171.68)	<0.001

HR	CI	р
0.30	(0.090.96)	0.043
0 73	(0.39 1.37)	0 327

С

А

в

Pos. malaria rapid test





:

Figure 3. Hazard ratio forest plot of 12-month mortality risk a











6

5

75

А

С



No. at Risk:

HIV-positive 134 (9) 124 (1) 123 (0) 123 (4) 119 (2) 117 (2) 113 (0) 113 HIV-negative 290(15)272 (5) 267 (4) 263 (3) 258 (0) 258 (1) 246 (0) 245

